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Glycogen metabolismMuscle glycogen phosphorylase (GP) plays an important role in muscle functions. Mercury has toxic
effects in skeletal muscle leading to muscle weakness or cramps. However, the mechanisms under-
lying these toxic effects are poorly understood. We report that GP is irreversibly inhibited by
inorganic (Hg2+) and organic (CH3Hg+) mercury (IC50 = 380 nM and kinact = 600 M1 s1 for Hg2+ and
IC50 = 43 lM and kinact = 13 M1 s1 for CH3Hg+) through reaction of these compounds with cysteine
residues of the enzyme. Our data suggest that the irreversible inhibition of GP could represent one of
the mechanisms that contribute to mercury-dependent muscle toxicity.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Muscle glycogen phosphorylase (GP, EC 2.4.1.1) is the rate-lim-
iting enzyme of glycogen breakdown in skeletal muscle [1].
Mutations that impair GP activity leads to McArdle’s disease which
is characterized by exercise intolerance, muscle fatigue, and
cramps [2,3].
Mercury is a widespread occupational and environmental pol-
lutant [4]. Inorganic (Hg2+) and organic mercury (CH3Hg+) exerts
a wide range of toxic effects through different mechanism. The
toxicity of inorganic and organic mercury is thought to be caused
primarily by binding and subsequent loss of protein functions
[5]. In addition to lungs, kidney and nervous system, deposition
of mercury in skeletal muscle also occurs [4]. Importantly, mercury
has been shown to contribute to skeletal muscle symptoms such as
muscle weakness and cramps and to induce myopathic changes in
rats [6,7]. Although the underlying toxicological mechanisms are
poorly understood, inhibition of key muscle enzymes such as
sarcoplasmic reticulum ATPases by mercury have been reported
[8]. Moreover, exposure to mercury of rats has been shown to alterthe metabolism of glycogen (elevation of glycogen levels) in the
liver and kidneys of rat and zebraﬁsh [9–11].
We show here that mercury impairs the glycogenolytic activity
of muscle GP. Mercury was able to inhibit endogenous GP enzyme
in skeletal muscle cells and in mouse extensor digitorum longus
(EDL) muscle extracts. The inhibition of GP by these chemicals is
a irreversible biomolecular process that relies on the formation
of a thiol–Hg bond involving cysteine residues. The irreversible
inhibition of GP could represent one of the mechanisms that
contribute to mercury-dependent muscle toxicity.2. Materials and methods
2.1. Materials
Glycogen phosphorylase (GP) in its b form was prepared from
rabbit skeletal muscle according to Fischer and Krebs using
b-mercaptoethanol instead of cysteine for crystallization [12].
Glucose-6-phosphate dehydrogenase (G6P-DH) and monoclonal
anti-ﬂuorescein were purchased from Roche. Otherwise noted, all
other compounds were from Sigma.
2.2. GP activity assay
The measurement of GP activity was carried out in the direction
of glycogen breakdown in presence of AMP, as previously
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coupled assay system containing phosphoglucomutase, G6P-DH
and NADP, by reading NADPH formation at 340 nm. The phosphor-
ylase activity assay was carried out at 37 C in 50 mM glycine–gly-
cine (gly–gly) buffer, pH 6.8. Brieﬂy, the reaction mixtures
consisted of pure GP (or cell/tissue extracts), 2 mg/ml glycogen,
16 mM Pi, 0.8 mM AMP, 8 mMmagnesium acetate, 0.64 mMNADP,
5.88 lM glucose 1,6-diP, 0.128 units of phosphoglucomutase and
0.0875 units of G6P-DH in a ﬁnal volume of 250 ll. Each reaction
was performed in triplicate.
2.3. Effects of mercury on GP activity
Prior to any experiment, GP enzyme was reduced by 10 mM
dithiothreitol (DTT) at 0 C for 30 min and then dialysed overnight
at 4 C against 50 mM gly–gly buffer. Protein concentration was
determined using a Bradford assay with BSA (Bovine serum
albumin) as standard (Bio-rad). Mercury and GP (0.5 lM ﬁnal con-
centration) reactions were carried out in 50 mM gly–gly buffer (pH
6.8) at 37 C for 30 min followed by dilution (50 times) with
gly–gly buffer prior to enzyme assay.
To test whether the reaction of GP with mercury was irrevers-
ible, puriﬁed enzyme (0.5 lM ﬁnal) was ﬁrst incubated in presence
or absence of mercury for 30 min at 37 C. The samples were then
dialysed overnight at 4 C against gly–gly buffer prior to enzyme
assay. Controls were carried out with non dialysed samples.
To test whether the mercury-dependent inhibition of GP could
be reversed by reducing or chelating agents, GP (0.5 lM ﬁnal) was
ﬁrst inhibited by mercury for 30 min at 37 C. Samples were then
diluted (50 times) with gly–gly buffer containing different concen-
trations of reduced glutathione (GSH) or ethylenediaminetetraace-
tic acid (EDTA) and further incubated for 15 min at 37 C prior to
enzyme assay.
2.4. Kinetic analysis of inhibition of GP by mercury
In order to determine the second-order rate constant for inhibi-
tion of GP, equimolar concentrations of GP and mercury were
incubated in 50 mM gly–gly buffer (pH 6.8) at 25 C as described
previously [14]. Aliquots were withdrawn every 6 min, diluted
with gly–gly buffer (50 times) and assayed for residual enzyme.
Controls were carried out in absence of mercury. The kinact value
was determined by ﬁtting data to the following equation: E0/
E = 1 + kinactE0t, where E is the active enzyme concentration
(residual activity), E0 is the initial enzyme concentration (initial
activity) and t is time.
2.5. Effects of mercury on GP cysteine residues
Free cysteine residues in GP (before and after treatment with
mercury) were analysed in two ways. First, free cysteines were de-
tected by irreversible labeling with ﬂuorescein-conjugated iodoa-
cetamide. To this end, GP (0.5 lM) was incubated with or
without different concentrations of mercury in 50 mM gly–gly
buffer (pH 6.8) at 37 C for 30 min. Samples were then diluted in
gly–gly buffer containing 5-IAF (20 lM ﬁnal) and incubated for
30 min at 37 C. Samples were then dot-blotted on nitrocellulose
using a Bio-rad dot-blot apparatus according to manufacturer’s
instructions. Detection of labeled-free cysteines and GP protein
were carried out using anti-ﬂuorescein antibody and Ponceau S
stain, respectively, as described previously [15].
DTNB (5,50-dithiobis-(2-nitrobenzoic acid) was used to quantify
the number of cysteine residues in GP that reacts with mercury as
previously described [16,17]. To this end, reduced GP (2.0 lMﬁnal)
was incubated with mercury at a concentration that gives 100%
inhibition (4.0 lM ﬁnal for HgCl2) in 50 mM gly–gly buffer (pH6.8) at 37 C for 60 min. DTNB (1.0 mM in 3.0 M guanidinium
chloride ﬁnal) was added and the mixture further incubated for
60 min at room temperature. Absorbance of TNB anion (2-nitro-
5-thiobenzoate) was measured at 412 nM. Reaction of DTNB with
free cysteines is stoichiometric so that TNB- concentration is equal
to free cysteine concentration. The number of free thiols was
calculated using a molar extinction coefﬁcient of 13700 M1 cm1.
2.6. Effects of mercury on the endogenous GP activity of cultured
myotubes
C2C12 mouse myoblast cells were grown in Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM) with 20% fetal bovine serum (FBS)
at 37 C in 100 mm petri dishes. C2C12 cells were differentiated
into myotubes by growing cells in 2% FBS. The resulting cultures
were determined to be >95% differentiated myotubes by visual
inspection. Myotube monolayers (90% conﬂuence) were washed
with PBS and exposed to different concentrations of mercury in
PBS for 45 min at 37 C. MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-di-
phenyl-2H-tetrazolium bromide) assays were carried out to ensure
that the concentrations of mercury were subtoxic in the conditions
used. After treatment, cells were scraped in lysis buffer (PBS with
0.1% Triton X-100 supplemented with protease/phosphatase inhib-
itors). Cell lysates were brieﬂy sonicated, centrifuged (13000g,
for 15 min) and GP activity measured in supernatants.
2.7. Effects of mercury on the endogenous GP activity of mouse
extensor digitorium longus (EDL) muscle
EDL muscles from a 3-months old male Swiss mice were dis-
sected, cut in pieces and homogenized in PBS 0.1% Triton X-100
supplemented with protease/phosphatase inhibitors using a tissue
glass Dounce homogenizer. After brief sonication, the homogenate
was centrifuged (13000g for 15 min). The supernatant was incu-
bated with different concentrations of mercury for 45 min at 37 C
and residual GP activity measured.
3. Results and discussion
3.1. Mercury inhibit the activity of puriﬁed and endogenous GP
enzyme
Mercury has been shown to deposit in skeletal muscle and to
exert symptoms such as muscle weakness and cramps. Geneti-
cally-based impairment of muscle GP enzyme is known to be the
cause of metabolic myopathy with different symptoms including
muscle fatigue and cramps [6,7]. Moreover, it has been shown that
exposure to mercury can alter the metabolism of glycogen in liver
and kidney of rats [9,10]. To test whether mercury could impact
the functions of muscle GP, we analyzed the effects of different lev-
els of Hg2+ (HgCl2) and CH3Hg+ (CH3HgCl) on the phosphorolysis of
glycogen by puriﬁed rabbit GP. Mammalian muscle GP enzymes
are highly conserved (amino acid identity >95%) and most studies
on muscle GP have been done with the rabbit enzyme, which
shares 98% identity with the human and mouse ortholog. As shown
in Fig. 1, exposure of GP to Hg2+ (HgCl2) or CH3Hg+ led to the dose-
dependent inhibition of the enzyme with half-maximal inhibitory
concentration (IC50) values of 0.38 ± 0.08 (Fig. 1A) and 43 ± 3 lM
(Fig. 1B), respectively. Hg2+ was found to be a more potent inhibi-
tor than CH3Hg+ with nearly 90% of the enzyme inhibited at a
concentration of 800 and 100 lM, respectively. Such a trend has
been shown for other enzymes inhibited by mercury [14,18]. We
investigated the ability of mercury to inhibit the activity of endog-
enous GP in cultured mouse myotubes. To this end, C2C12
myotubes (which are a well-known model of differentiated
skeletal muscle cells) were exposed to subtoxic doses of Hg2+
Fig. 1. Dose-dependent inhibition of GP. GP (0.5 lM) was incubated with different concentrations of HgCl2 (A) or MeHgCl (B) in 50 mM gly–gly buffer (pH 6.8) at 37 C for
30 min. After dilution with gly–gly buffer (50 times), the residual GP activity was determined. Data shown represent mean ± S.D., ⁄P < 0.05, ⁄⁄⁄P < 0.001 versus control (not
treated enzyme). (C) C2C12 myotube monolayers were exposed to different concentrations of HgCl2 for 45 min at 37 C. After treatment, cells were washed with PBS and total
proteins were extracted in PBS, 0.1% Triton X-100, supplemented with protease and phosphatase inhibitors. Normalized cell extracts (1 mg/ml) were used to measure GP
activity. (D) Extracts from mouse EDL muscle (in PBS, 0.1% Triton X-100 with protease and phosphatase inhibitors) were incubated with different concentrations of HgCl2 for
45 min at 37 C. The activity of GP in treated and non treated extracts (control) were measured. Data represent mean ± S.D., ⁄⁄⁄P < 0.001 versus control.
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was observed with nearly 90% inhibition obtained at 12.5 lM Hg2+
(Fig. 1C). To conﬁrm that endogenous GP could be inhibited by low
micromolar concentrations of Hg2+, tissues extracts made from
mouse extensor digitorum longus muscles were incubated with
Hg2+ for 45 min at 37 C. As observed with cultured myotubes,
endogenous GP was strongly inhibited by Hg2+ with nearly 80%
inhibition obtained at 10 lM concentration (Fig. 1D). Experiments
conducted with CH3Hg+ gave similar results but higher concentra-
tions were needed (>30 lM) (data not shown). Mercury can grad-
ually accumulate in tissues and reach micromolar concentrations
[11]. Concentrations up to 80 lM have been reported in blood
[5]. Altogether, these data conﬁrmed that the GP-dependent
phosphorolysis of glycogen in skeletal muscle can be inhibited by
mercuric compounds with the Hg2+ form being more potent than
CH3Hg+. As mentioned above, this latter point is in agreement with
data reported for other enzymes such as glutathione S-transferase
P1 [18], thioredoxin reductase [17] or arylamine N-acetyltransfer-
ases [14] which were found to be more sensitive to Hg2+ compared
to CH3Hg+. Interestingly it has been reported that after exposure to
CH3Hg+, inorganic mercury (Hg2+) accounts for more than 80% of
mercury present in CNS suggesting that toxicity of CH3Hg+ devel-
ops after demethylation [19].
3.2. Molecular and kinetic mechanisms of GP inhibition by mercury
Mercury toxicity has been related to its ability to form stable
complexes with sulfhydryl-containing molecules such as certain
cellular proteins [5,16,17].
To test whether the mercury-dependent inhibition of GP was
irreversible, dialysis experiments were carried out (Fig. 2A). HgCl2-
treated GP (1 lM HgCl2) showed a residual activity of only 8 ± 1%
and 6 ± 1% for dialysed and undialysed proteins, respectivelysuggesting the irreversible inhibition of GP by Hg2+. Inhibition of
GP by CH3Hg+ was also found to be irreversible (data not shown).
Further experiments were carried out with reduced glutathione,
a major cellular reducing agent known to react with mercury,
and with EDTA, a compound that is known to chelate mercury.
As shown in Fig. 2B, GSH at high concentrations (1–10 mM:
1000–10000-fold concentration over Hg2+ concentration) weakly
reactivated GP (30% reactivation). No reactivation was obtained
with EDTA (Fig. 2B). Similar data were obtained for GP inhibited
by CH3Hg+ (data not shown). All together our data support the
irreversible nature of the reaction of mercury compounds with
GP likely through the formation of Hg–thiol bonds [16,17]. Several
enzymes have been shown to be irreversibly inhibited by Hg2+ or
CH3Hg+ through binding to key cysteine residues [16,17]. Interest-
ingly, studies have shown that muscle GP contains certain cysteine
residues which chemical modiﬁcation leads to irreversible inhibi-
tion [20]. Therefore, to test whether mercury reacts with GP
cysteine residues, we incubated the puriﬁed enzyme with Hg2+ in
the concentration range shown to inhibit GP (Fig. 1). Free
unmodiﬁed cysteine residues in the enzyme were labelled with
ﬂuorescein-conjugated iodoacetamide and detected in dot blots
using an anti-ﬂuorescein antibody. As shown in Fig. 2C, Hg2+
reacted with GP cysteine residues in a dose-dependent manner,
as indicated by the disappearance of the ﬂuorescein signal. This
dose-dependent modiﬁcation was correlated with the dose-depen-
dent inhibition of GP by Hg2+ (Fig. 1), supporting that the processes
are linked. Similar results were obtained with CH3Hg+ (data not
shown). Quantiﬁcation of free GP cysteine upon incubation with
Hg2+ was carried out spectrophotometrycally with the cysteine
selective agent 5,50-dithiobis(2-nitrobenzoic acid) (DTNB) as
described previously [16]. We found that full inhibition of GP by
Hg2+ or CH3Hg+ was concomitant with the modiﬁcation of four
cysteine residues per monomer of enzyme (out of nine). These
Fig. 2. Irreversibility of GP inhibition by HgCl2 and modiﬁcation of cysteine
residues of GP. (A) GP (0.5 lM) in 50 mM gly–gly buffer (pH 6.8) was incubated for
30 min at 37 C in absence or presence of HgCl2 (1 lM ﬁnal). Samples were dialyzed
overnight at 4 C against gly–gly buffer (open bars) or kept at 4 C (black bars) and
subsequently assayed for GP activity. (B) GP (0.5 lM) in 50 mM gly–gly buffer (pH
6.8) was incubated for 30 min at 37 C in absence or presence of HgCl2 (1 lM ﬁnal).
Treated and non treated samples were diluted with gly–gly buffer (50 times) and
incubated in presence of high concentrations of GSH or EDTA (15 min at 37 C).
Then samples were assayed for GP activity. Data represent mean ± S.D., #P < 0.05,
###P < 0.001 versus control; ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 versus activity of GPb
exposed to HgCl2. (C) GPb (0.8 lM) in 50 mM gly–gly buffer (pH 6.8) was incubated
with different concentrations of HgCl2 for 30 min at 37 C. Samples were further
incubated with 5-IAF (20 lM ﬁnal) for 30 min in the dark at room temperature.
Samples were then dot-blotted on nitrocellulose using a Bio-rad apparatus. 5-IAF
binding to GP was determined using antibodies against ﬂuorescein (upper lane).
The GP protein in the nitrocellulose sheet was stained with Ponceau S (lower lane).
  
Fig. 3. Effect of AMP on HgCl2-dependent inhibition of GP. GP (0.5 lM) in 50 mM
gly–gly buffer (pH 6.8) was ﬁrst preincubated with AMP (2.5 mM) for 15 min at
37 C prior to incubation with HgCl2 for 30 min at 37 C. Before mixing GP (0.5 lM
ﬁnal) with HgCl2 (1 lM), GP was incubated with AMP (2.5 mM) for 15 min at 37 C.
After dilution in gly–gly buffer (50 times), samples were assayed for GP activity.
Data represent mean ± S.D., ⁄P < 0.05, ⁄⁄⁄P < 0.001 versus control (without HgCl2
treatment); ⁄⁄P < 0.01 versus activity of GP exposed to HgCl2.
Fig. 4. Kinetic analysis of GP inhibition by HgCl2. Determination of the second-
order rate constant (kinact) for inhibition of GP by HgCl2 was carried out under
second-order conditions. Brieﬂy, GP (0.5 lM) and HgCl2 (0.5 lM) were incubated in
50 mM gly–gly buffer (pH 6.8) at 25 C. At determined intervals (every 6 min),
aliquots were taken and residual GP activity was assayed after dilution (50 times)
with gly–gly buffer (upper panel, black squares represent residual activity of HgCl2-
treated enzyme as a function of time whereas black circles represent residual
activity of non treated enzyme). kinact was obtained by ﬁtting the data shown in the
upper panel to Eq. (1) and taking kinact from the slope of E0/E versus time (lower
panel).
X. Xu et al. / FEBS Letters 588 (2014) 138–142 141results are in agreement with other studies showing that only up 3
to 4 cysteine residues of native GP could be modiﬁed by cysteine
reagents such as iodoacetamide or 2,4-dinitrochlorobenzene [20].
The remaining 5 to 6 cysteine residues of each monomer are pro-
tected by the tertiary/quaternary structure of the protein and are
not readily accessible to reagents such as mercury [20]. More
importantly, it has been shown that among these accessible
cysteine residues of native GP, the modiﬁcation of cysteine 142
was the major responsible for the loss of activity of GP [20]. Inter-
estingly, contrary to other cysteine residues of GP, modiﬁcation of
this cysteine is known to be not prevented by AMP binding [20]. As
shown in Fig. 3, ligand protection assays with AMP at saturating
concentrations showed that it was unable to protect completely
GP from inhibition by Hg2+. These results are in agreement with
142 X. Xu et al. / FEBS Letters 588 (2014) 138–142the data discussed above [20] and support that irreversible
modiﬁcation of cysteine 142 by mercury is likely to contribute
signiﬁcantly to mercury-dependent inhibition of GP. However,
modiﬁcation of other cysteine residues by mercury may also be
involved in inhibition to some extent.
Further kinetic characterization of GP inhibition by Hg2+ was
carried out under second order conditions. As shown in Fig. 4,
the reaction between GP and Hg2+ followed an irreversible fast
bimolecular process with a second-order rate constant for inhibi-
tion equal to 6.102 M1 s1. Liver glutathione peroxidase was
found to be irreversibly inhibited by Hg2+ with a similar kinetic
process (kinact = 2.102 M1 s1). Reaction of GP with CH3Hg+ was
found to be much slower with a second-order rate constant of
13 M1 s1. Such a trend has been shown for other enzymes inhib-
ited by Hg2+ and CH3Hg+ such as arylamine N-acetyltransferase
[14].
Mercury in both organic and inorganic forms exerts a wide
range of toxic effects and affects different tissues in particular kid-
neys and CNS [4]. Although the mechanism of mercury toxicity is
complex, the chemical propensity of mercury for sulhydryl groups
contributes to its transport, disposition and toxicity in the body
[17]. To better understand mercury toxicity, identiﬁcation and
characterization of its molecular targets in different tissues is
needed. Mercury has also been shown to accumulate in skeletal
muscle and to exert symptoms such as muscle weakness and
cramps [6]. In addition, exposure to mercury has been reported
to affect glycogen metabolism in rodent liver and kidney with
accumulation of glycogen [9,10]. Here we report that GP, the key
enzyme of glycogen metabolism in skeletal muscle is irreversibly
inhibited by Hg2+, at concentration levels associated with clinical
toxicity [5]. CH3Hg+ was also found to impair GP functions in a sim-
ilar manner but at higher concentrations. Such a trend has been
shown for other targets of mercury such as the human thioredoxin
reductase [17].
Impairment of muscle GP is well-known to lead to metabolic
disorders and muscle disfunction. Our data suggest that mercury-
dependent inhibition of GP could contribute to the toxicity of this
metal in skeletal muscle.
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